CBIO — CRESCENT BIOPHARMA, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1253689 ·
Last close
$13.04
Market Cap
$507.20M
52W High
$27.41
52W Low
$8.72
ADV30
268,813
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,117,000 | — | -39,907,000 | -37,726,000 | 299,503,000 | 289,357,000 | 25,224,000 |
| Jun 2026 | 0 | — | -26,364,000 | -24,837,000 | 182,758,000 | 171,593,000 | 19,503,000 |
| Mar 2026 | 1,039,000 | — | -24,729,000 | -23,283,000 | 199,130,000 | 189,163,000 | 15,283,000 |
| Dec 2025 | 10,844,000 | — | -91,492,000 | -92,397,000 | 240,293,000 | 213,192,000 | 37,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,679,000
Investing CF
$-79,169,000
Financing CF
$170,797,000
CapEx
$-80,939,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.72
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-219,929,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-163,124,000
Pretax Income TTM
$-163,124,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,000,000
EBITDA
$-184,011,008
Free Cash Flow
—
Enterprise Value
$269,787,456
Total Cash
$289,356,992
Total Debt
$2,458,000
Shares Out
38,895,442
Trailing EPS
$-7.63
Book Value
$4.77
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,844,000 | -152,632,000 | -153,942,000 | 240,293,000 | 37,281,000 | 203,012,000 | -71,532,000 |
| Dec 2024 | — | — | — | 35,617,000 | 51,096,000 | -15,479,000 | — |
TTM Snapshot
Revenues TTM
$11,883,000
NetIncome TTM
$-177,928,264
OpCashFlow TTM
—
Assets (Latest)
$182,758,000
Forward EPS
$-2.63
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $12.40 · call volume: 17 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVO | Evotec SE | $525.98M | $1.48 | — |
| HELP | Helus Pharma Inc. | $526.03M | $7.20 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $488.98M | $8.41 | — |
| GYRE | GYRE THERAPEUTICS, INC. | $488.23M | $4.56 | — |
| MNPR | Monopar Therapeutics | $481.56M | $71.06 | — |
News headlines (Yahoo Finance, 1h cache)
Crescent Biopharma: Q3 Earnings Snapshot
2026-11-12 21:47 · Yahoo
Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-12 21:15 · Yahoo
Crescent Biopharma Announces Grants of Inducement Awards
2026-11-03 21:15 · Yahoo
Crescent Biopharma to Present at November Investor Conferences
2026-11-02 12:30 · Yahoo
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis
2026-10-15 20:15 · Yahoo
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors
2026-10-05 11:30 · Yahoo
Crescent Biopharma to Present at September Investor Conferences
2026-09-03 11:30 · Yahoo
Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-07-16 20:01 · Yahoo
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-15 01:45 · Yahoo
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
2026-07-14 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.